UnitedHealth dropped the latest formulary bomb Wednesday with a proposal to exclude Sanofi’s insulin Lantus and Amgen’s infection-fighter Neupogen in favor of…

Allergan has shown recently that it may just intend to stick to the “stepping stone deals” script it’s been talking up--at least, for now. But that hasn’t…

Congressional committee members and Mylan CEO Heather Bresch exchanged some harsh words Wednesday during a contentious EpiPen hearing. But as little weight as…

England’s cost watchdogs are changing their tune on Alexion’s rare bone disorder drug Strensiq--but not quite as much as the drugmaker would like.

Less than two weeks after a report highlighted complaints from agents at the FDA’s criminal office, a U.S. congressional committee has decided to take a closer…

Political pressure is building in Mylan’s EpiPen pricing scandal, including a probe in West Virginia that is hinting at the possibility of Medicaid fraud.  

Bayer is looking to sell off its dermatology unit to help drum up cash for its $66 billion Monsanto buy--and rumor has it, it’s got plenty of takers.

It's no secret that Gilead offered steep discounts to win formulary spots for its blockbuster hep C meds Sovaldi and Harvoni. Now, we have numbers--and…